James Sullivan
Technik-/Wissenschafts-/F&E-Leiter bei ENGENE HOLDINGS INC.
Aktive Positionen von James Sullivan
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ENGENE HOLDINGS INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.11.2023 | - |
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Technik-/Wissenschafts-/F&E-Leiter | 01.02.2022 | - |
Karriereverlauf von James Sullivan
Ehemalige bekannte Positionen von James Sullivan
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
TRANSLATE BIO, INC. | Corporate Officer/Principal | 01.01.2021 | 01.02.2022 |
SANA BIOTECHNOLOGY, INC. | Direktor/Vorstandsmitglied | 01.08.2019 | 01.01.2021 |
Corporate Officer/Principal | 01.08.2019 | 01.01.2021 |
Ausbildung von James Sullivan
Boston College | Undergraduate Degree |
University College Dublin | Graduate Degree |
Boston University | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 5 |
Kanada | 3 |
Irland | 2 |
Operativ
Corporate Officer/Principal | 2 |
Chief Tech/Sci/R&D Officer | 2 |
Undergraduate Degree | 1 |
Sektoral
Health Technology | 5 |
Consumer Services | 4 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
SANA BIOTECHNOLOGY, INC. | Health Technology |
ENGENE HOLDINGS INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Translate Bio, Inc.
Translate Bio, Inc. BiotechnologyHealth Technology Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidate, MRT5005 is designed for the treatment of cystic fibrosis. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA. | Health Technology |
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Health Technology |
- Börse
- Insiders
- James Sullivan
- Erfahrung